Effects of Pegylated Interferon alpha on Fibrinolytic Parameters in Patients With Chronic Hepatitis C

Interferon (IFN) interacts with endothelial cells and modulates the functions of these cells. In our study, we aimed to determine the effects of treatment with pegylated IFN-alpha (peg-IFN-alpha) on fibrinolytic parameters in patients with chronic hepatitis C. Fifteen patients with chronic hepatitis C were treated with peg-IFN-a once per week plus daily oral ribavirin. Euglobulin lysis time (ELT), plasma levels of D-dimer, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined before treatment, 2 weeks, 1 month, and 3 months after the initiation of the treatment. Plasma levels of t-PA increased significantly 1 month and 3 months after the treatment (P < .05). The PAI-1 and TAFI levels in 2 weeks, 1 month and 3 months after treatment were not statistically different as compared with pretreatment levels (P > .05) No significant difference in plasma D-dimer levels was observed during peg-IFN-alpha treatment (P > .05). There was a significant decrease in ELT 1 month and 3 months after the treatment (P < .05). Our results indicated that treatment with peg-IFN-alpha may be associated with enhanced fibrinolysis,

Yazar Gokmen, Ayla
Ustundag, Yucel
Oztoprak, Nefise
Aydemir, Selim
Tekin, Ishak Ozel
Cakal, Basak
Kiran, Sibel
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/2502
Tek Biçim Adres 10.1177/1076029610371475
Konu Başlıkları chronic viral hepatitis
interferon
fibrinolysis
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
Dergi Cilt Bilgisi 17
Dergi Sayısı 5
Sayfalar 449 - 453
Yayın Yılı 2011
Eser Adı
[dc.title]
Effects of Pegylated Interferon alpha on Fibrinolytic Parameters in Patients With Chronic Hepatitis C
Yazar
[dc.contributor.author]
Gokmen, Ayla
Yazar
[dc.contributor.author]
Ustundag, Yucel
Yazar
[dc.contributor.author]
Oztoprak, Nefise
Yazar
[dc.contributor.author]
Aydemir, Selim
Yazar
[dc.contributor.author]
Tekin, Ishak Ozel
Yazar
[dc.contributor.author]
Cakal, Basak
Yazar
[dc.contributor.author]
Kiran, Sibel
Yayın Yılı
[dc.date.issued]
2011
Yayıncı
[dc.publisher]
SAGE PUBLICATIONS INC
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Interferon (IFN) interacts with endothelial cells and modulates the functions of these cells. In our study, we aimed to determine the effects of treatment with pegylated IFN-alpha (peg-IFN-alpha) on fibrinolytic parameters in patients with chronic hepatitis C. Fifteen patients with chronic hepatitis C were treated with peg-IFN-a once per week plus daily oral ribavirin. Euglobulin lysis time (ELT), plasma levels of D-dimer, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined before treatment, 2 weeks, 1 month, and 3 months after the initiation of the treatment. Plasma levels of t-PA increased significantly 1 month and 3 months after the treatment (P < .05). The PAI-1 and TAFI levels in 2 weeks, 1 month and 3 months after treatment were not statistically different as compared with pretreatment levels (P > .05) No significant difference in plasma D-dimer levels was observed during peg-IFN-alpha treatment (P > .05). There was a significant decrease in ELT 1 month and 3 months after the treatment (P < .05). Our results indicated that treatment with peg-IFN-alpha may be associated with enhanced fibrinolysis,
Açıklama
[dc.description]
WOS: 000295613900002
Açıklama
[dc.description]
PubMed: 20699259
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
chronic viral hepatitis
Konu Başlıkları
[dc.subject]
interferon
Konu Başlıkları
[dc.subject]
fibrinolysis
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
1076-0296
İlk Sayfa Sayısı
[dc.identifier.startpage]
449
Son Sayfa Sayısı
[dc.identifier.endpage]
453
Dergi Adı
[dc.relation.journal]
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
Dergi Sayısı
[dc.identifier.issue]
5
Dergi Cilt Bilgisi
[dc.identifier.volume]
17
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1177/1076029610371475
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/2502
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
211
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
11 Haziran 2024 23:12
Google Kontrol
Tıklayınız
treatment levels months hepatitis activator plasma D-dimer plasminogen inhibitor fibrinolysis chronic patients significant peg-IFN-alpha indicated increased results initiation Plasma decrease associated enhanced significantly during statistically different compared pretreatment observed difference Interferon (t-PA) before (peg-IFN-alpha) IFN-alpha
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms